Drug Target Review

Skip to main content
Skip to navigation

Featured content

Women in STEM: resilience and leadership in rare disease research

2026-05-19T09:46:00+01:00Contributor Dr Nitza Thomasson

Rare neurological diseases remain one of the most challenging areas in drug discovery, with many patients still lacking treatment options. Dr Nitza Thomasson discusses returning to Servier to lead its rare neurology therapeutic area and explains why resilience, curiosity and persistence are essential for those looking to build a meaningful career in STEM.

Article
Drug Target Review launches new website designed for drug discovery professionals
2026-04-30T07:00:00+01:00
Drug Target Review has launched an updated website to improve access to content across early-stage drug discovery, alongside a new membership model that offers a gateway to premium analysis, reports and expert commentary.
Article
When scale meets insight: reinventing SPR for the future of drug discovery
2026-04-30T09:08:00+01:00By Carterra
Carterra’s new 48-channel SPR platform reimagines throughput, automation and data quality for modern discovery workflows.
Article
From constraint to catalyst: innovation in rare disease clinical development
2026-04-29T07:00:00+01:00By Dr Gen Li
Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence generation, trial design and regulatory thinking that could influence the future of clinical development.

Opinion and interviews

Computational design drives new generation of synthetic promoters

2026-03-26T14:21:00+00:00By Drug Target Review

Designing gene control from scratch is becoming possible. SynGenSys is using computational design to create synthetic promoters for advanced therapies.

Previous
Next

Webinars

Previous
Next

Whitepapers

Previous
Next

Transform your drug discovery pipeline with 3D cellular models